NEW YORK (360Dx) – RPRD Diagnostics today announced it and Orient Bio have inked a memorandum of understanding that will expand the availability of RPRD's pharmacogenomic testing services to South Korea.

Additionally, Orient Bio will diversify its business to include new areas, including precision medicine and clinical PGx, said RPRD, which stands for Right Patient Right Drug.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.